How Much Does Liver biopsy Cost in China?
Liver biopsy in China typically costs from $550 to $1,300. The final bill depends on the hospital setting, biopsy guidance, pathology review, and extra lab tests. In the US, similar procedures average $5,000. Patients save around 81% compared with the US. Some quotes bundle biopsy, imaging guidance, and pathology. Patients should check which services each estimate includes.
- Hospital setting: Local public hospitals may subsidize costs for eligible residents. International departments quote cash-pay services, which may include guidance and pathology.
- Imaging guidance: Ultrasound or CT guidance may add imaging fees when billed separately. Patients can check whether their quote includes this service.
- Pathology and lab work: Detailed tissue review, liver panels, or hepatitis tests add separate services. Their inclusion affects the total amount to budget.
- Noninvasive tests: FibroScan, enhanced MRI, or blood panels may cost less than biopsy. These tests sometimes replace needle sampling.
- City estimates: Patients can compare quotes from Beijing, Shanghai, and Guangzhou. They should check whether each estimate includes imaging guidance and pathology.
| China | Turkey | Austria | |
|---|---|---|---|
| Liver biopsy | ≈ $550 | from $600 | ≈ $900 |
Your Benefits and Guarantees with Bookimed
Transparent Prices & Flexible Installments
No hidden fees – just official clinic prices. Pay at the clinic for Liver biopsy upon arrival and use a flexible installment plan if needed.
Verified Clinics & Doctors Only
Bookimed is committed to your safety. We only work with medical institutions that maintain high international standards in Liver biopsy and have the necessary licenses to serve international patients worldwide.
Free 24/7 Assistance
Bookimed offers free expert assistance. A personal medical coordinator supports you before, during, and after your treatment, solving any issues. You're never alone on your Liver biopsy journey.

Your personal Bookimed medical coordinator
- Supports you at every stage
- Helps choose the right clinic and doctor
- Ensures quick and convenient access to information
Discover the Best Liver biopsy Clinics in China: 1 Verified Option and Prices
Our Doctors
View all Doctors
Liao Zhengyin
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.

Luo Xiaoping
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).

Xiao Yueyong
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.

Liu Shi Xin
Dr. Liu Shi Xin is the Vice Chairman of the Radiation Oncology Branch of the Chinese Medical Association. He serves as the Discipline Leader of the Oncology Center at Xiamen Humanity Hospital. Dr. Liu specializes in precision radiotherapy for thoracic and abdominal cancers. He is a recipient of the State Council Special Government Allowance for his medical contributions.
- Highly proficient in IMRT, VMAT, and SBRT for lung and esophageal cancers.
- Former President of Jilin Provincial Cancer Hospital.
- Awarded the National Famous Doctor honor for outstanding contributions to oncology.
- Holds leadership roles in the Chinese Anti-Cancer Association particle therapy committee.
Video Stories from Bookimed Patients
Share this content
Anna Leonova

